[
    [
        {
            "time": "",
            "original_text": "恒瑞医药：新技术平台、多治疗领域布局 国际化进程可期",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "新技术平台",
                    "多治疗领域",
                    "国际化进程"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞医药：新技术平台、多治疗领域布局 国际化进程可期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药HR19003贴剂获临试批准",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "HR19003",
                    "贴剂",
                    "临试批准"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞医药HR19003贴剂获临试批准",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "恒瑞市值年内缩水四成，63岁孙飘扬被迫再出山",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "市值缩水",
                    "孙飘扬",
                    "出山"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞市值年内缩水四成，63岁孙飘扬被迫再出山",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "产经报道 | 恒瑞医药：行业竞争加剧，没人能够“躺平”",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "行业竞争",
                    "加剧",
                    "躺平"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "产经报道 | 恒瑞医药：行业竞争加剧，没人能够“躺平”",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业2021年8月投资策略：布局业绩确定 估值合理标的",
            "features": {
                "keywords": [
                    "医药生物",
                    "投资策略",
                    "业绩确定",
                    "估值合理"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业2021年8月投资策略：布局业绩确定 估值合理标的",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "人民金融·创新药指数涨0.97% | 首个狂犬单抗药要来了，第五款国产PD-1获批上市",
            "features": {
                "keywords": [
                    "创新药指数",
                    "狂犬单抗药",
                    "国产PD-1",
                    "获批上市"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "人民金融·创新药指数涨0.97% | 首个狂犬单抗药要来了，第五款国产PD-1获批上市",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药官宣新董事长！多家知名药企高层变动",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "新董事长",
                    "药企高层变动"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞医药官宣新董事长！多家知名药企高层变动",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "爱徒难担大任，“药神”孙飘扬被迫出山",
            "features": {
                "keywords": [
                    "孙飘扬",
                    "药神",
                    "被迫出山"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "爱徒难担大任，“药神”孙飘扬被迫出山",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "A股融资融券日报：两融余额增加114.45亿元（8月4日）",
            "features": {
                "keywords": [
                    "A股",
                    "融资融券",
                    "两融余额",
                    "增加"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额增加114.45亿元（8月4日）",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药申报第5款ADC新药",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "ADC新药",
                    "申报"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞医药申报第5款ADC新药",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "新能源满屏涨停，游资且战且退，北上资金却默默加仓“老白马”",
            "features": {
                "keywords": [
                    "新能源",
                    "涨停",
                    "游资",
                    "北上资金",
                    "老白马"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "新能源"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "新能源满屏涨停，游资且战且退，北上资金却默默加仓“老白马”",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]